1. Home
  2. BANX vs SPRO Comparison

BANX vs SPRO Comparison

Compare BANX & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ArrowMark Financial Corp.

BANX

ArrowMark Financial Corp.

HOLD

Current Price

$19.60

Market Cap

154.9M

Sector

Finance

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.78

Market Cap

135.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BANX
SPRO
Founded
N/A
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
154.9M
135.5M
IPO Year
2013
2017

Fundamental Metrics

Financial Performance
Metric
BANX
SPRO
Price
$19.60
$2.78
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
34.8K
365.1K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
111.81
EPS
N/A
0.15
Revenue
N/A
$66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$300.00
P/E Ratio
N/A
$18.53
Revenue Growth
N/A
39.24
52 Week Low
$18.45
$0.58
52 Week High
$23.67
$3.09

Technical Indicators

Market Signals
Indicator
BANX
SPRO
Relative Strength Index (RSI) 55.58 66.10
Support Level $18.55 $2.15
Resistance Level $21.08 $3.09
Average True Range (ATR) 0.27 0.15
MACD 0.09 0.04
Stochastic Oscillator 100.00 85.07

Price Performance

Historical Comparison
BANX
SPRO

About BANX ArrowMark Financial Corp.

ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: